The prevalence of diabetes mellitus is estimated to be 8.3%, affecting ~387 million people as of 2014, and expected to affect ~592 million people by 2035
. Although intense, multifactorial intervention strategies reduce the risk of macroangiopathy and microangiopathy in patients with type 2 diabetes mellitus (T2DM) 3 , 77% of affected patients live in lowto-middle-income countries where efficient therapeutic modalities for T2DM and its complications may be limited. Chronic inflammation is regarded as an important mechanism for the development of both diabetes mellitus and its associated vascular diseases, such as diabetic nephropathy 4 ; the identification of new molecules associated with the innate immune system has prompted many researchers to investigate their role in the sustained inflammatory response in type 1 diabetes mellitus (T1DM) and T2DM.
In contrast to the adaptive immune system, the innate immune system can detect and eliminate the majority of insults elicited by microorganisms within minutes or hours, using defense mechanisms that are independent of the clonal expansion of antigen-specific lymphocytes 5 . These mechanisms include the recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (PRRs). In addition to sensing microorganism byproducts, the innate immune system has evolved to detect endogenous danger signals through the sensing of danger-associated molecular patterns (DAMPs) 6 . DAMPs are derived from damaged or dying cells, and include small molecules (ATP and DNA), particles (uric acid crystals and exogenous noxious factors such as asbestos) and environmental insults such as ultraviolet radiation 7 . Systemic and local low-grade inflammation and release of proinflammatory cytokines are implicated in the pathogenesis of T1DM and T2DM. Furthermore, among the vascular complications of diabetes mellitus, subclinical inflammation is also known to contribute to the pathogenesis of diabetic nephro pathy 4, 8, 9 . In this Review we provide an update on the functional roles of Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD)-like receptors (NLRs) in the pathogenesis of T1DM and T2DM and its vascular complications, namely diabetic nephropathy 10 . We especially focus on the role of TLR2, TLR4, and NLRP3 and discuss the bene fits and limitations of targeting these molecules in the treatment of diabetes mellitus and diabetic nephropathy.
PRRs of the innate immune system

Toll-like receptors
The innate immune system includes several classes of PRRs, including membrane-bound TLRs and C-type lectin receptors (CLRs), which detect PAMPs and DAMPs in the extracellular space and endosomal compartment (TABLE 1) . TLRs are type 1 membrane glycoproteins with a characteristic cytoplasmic Toll/IL-1 receptor (TIR) domain and a leucine-rich repeat domain 11, 12 . TLRs recognize PAMPs, such as lipopolysaccharide (LPS), lipopeptides, flagellin, bacterial DNA, and viral doublestranded RNA (dsRNA) 13 , as well as endogenous DAMPs, including HMGB1 and β-defensins 11 . The TLR signalling pathways are finely tuned by TIR domain-containing adaptors, such as MyD88, TIR domain-containing adaptor protein/MyD88 adaptor-like protein (TIRAP), TIRdomain-containing adaptor-inducing IFN-β (TRIF), and TRIF-related adaptor molecule (TRAM). The TIR domain consists of three boxes of conserved residues set in a core sequence of 135-160 amino acids, which facilitate receptor-adaptor oligomerization 14 . The differential recruitment of these adaptor proteins results in the formation of a myddosome complex -an oligomeric signalling complex that consists of the adaptor proteins MyD88, IRAK1 and IRAK4 -and activation of various signalling molecules, such as NF-κB, MAPK, and interferon regulatory factor (IRF), and the subsequent production and release of various cytokines and chemokines [15] [16] [17] [18] [19] (FIG. 1) .
NOD-like receptors
NLRs constitute another set of intracellular sensing PRRs that are localized in the cytosol and are essential for sensing invading pathogens and prompting an innate immune response 20 . Intracellular NLRs organize signalling complexes, such as NOD signalosomes (a protein complex involved in the regulation of protein degradation by ubiquitination 21 ) and inflamma somes (a multi-protein molecular scaffold complex) 22 . NOD1 and NOD2 are well-characterized NLRs in the NOD signalosome, which upon activation homo-oligomerize and recruit signalling molecules that drive NF-κB-dependent and AP1-dependent production of proinflammatory cytokines 23 (FIG. 2) . Some inflamma somes have been shown to activate caspase-1, convert premature forms of IL-1β, IL-18, and IL-33 to mature forms, and secrete these cytokines into the extra cellular space 24 . Each NLR contains N-terminal effector domains, such as the caspase activation and recruitment domain (CARD), pyrin domain (PYD), and the baculoviral inhibitor of apoptosis protein repeat domain (BIR), and are divided into subfamilies based on the composition of these domains [25] [26] [27] . All NLRs contain a central nucleotide binding and oligomerization (NACHT) domain and most members have a variable number of ligand-sensing C-terminal leucine-rich repeat (LRR) domains [25] [26] [27] (FIG. 2) .
Inflammasomes
Several inflammasomes with different sensor proteins, such as NLRP1, NLRP3, IPAF, NLRP6, RIG-1, and AIM2, can oligomerize to form multi-protein inflamma some complexes. NLRP1 or NLRP3 oligomerize, for example, via the NACHT domain (a 300-400 amino acid NTPase domain), which results in subsequent clustering of PYDdomain-containing proteins and the recruitment of ASC (PYCARD), which contains a caspase recruitment domain to activate caspase-1. Activation of caspase-1 promotes the processing and secretion of IL-1β, IL-18, and IL-33 contributing to the inflammatory response 7, 19, 28 (FIG. 2) .
T1DM
Involvement of TLRs
T1DM is a well-established type 1 T-helper cell 1 (T H 1)-mediated disease in which pancreatic β cells are selectively injured and destroyed 29 . Many studies that have addressed the mechanisms of T1DM have focused on the role of the T-cell-mediated adaptive immune response. The discovery of TLRs has, however, improved understanding of the signalling pathways involved in innate immunity, which is important in promoting the autoreactive T-cell response that can initiate T1DM 30 . Experimental evidence to support the involvement of TLRs in T1DM is discussed below.
TLR2 and TLR4 in insulitis.
A TLR2 single nucleotide polymorphism haplotype, TLR2-Ht4, is strongly associated with T1DM, whereby more than one copy of TLR2-Ht4 confers strong protection from the development of T1DM 31 . Peptide p277, a 24-amino acid fragment of HSP60, has also been shown to arrest the spontaneous diabetogenic process that occurs in nonobese diabetic (NOD) mice following therapeutic vaccination 32 . p277 induces a cytokine profile shift from a T H 1 to a type 2 T-helper (T H 2) cell response by stimulating TLR2 signalling 32 . This shift was shown to promote integrin-mediated adhesion of T cells to fibronectin and inhibit their migration towards the pro-inflammatory chemotactic signal SDF-1α in vitro 32 . Furthermore, treatment of antigen-presenting cells in NOD mice with
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-/-and Tlr4 -/-mice into wild-type mice reduced the production of pro inflammatory cytokines and improved islet survival 38 . Together these findings suggest that inhibition of TLR2 and TLR4 signalling is beneficial in suppressing sustained inflammation in pancreatic islets; however, this approach may prompt the initiation of an adaptive immune response against autoantigens.
TLR2-mediated atherosclerosis.
Endothelial inflammatory responses mediated by TLR2 and TLR4 are involved in the progression of atherosclerosis associated with diabetes mellitus and obesity 39 . Treatment of cultured coronary artery endothelial cells derived from patients with T1DM with TLR2 agonist peptidoglycans and the TLR4 agonist LPS enhanced the expression of NF-κB, ICAM-1, IL-6, and IL-8 compared to levels in cells from nondiabetic individuals 40 . Furthermore, blockade of TLR2 in intact aortas using an anti-TLR2 antibody attenuated an increase in vascular contraction in rats treated with streptozotocin (STZ) -a naturally occurring chemical that has toxic effects on insulin-producing β cells -as assessed by wire myography. Activation of TLR2 in primary aortic vascular smooth muscle cell cultures triggered activation of RhoA, and was exacerbated in cells from STZ-diabetic rats 41 . Single nucleotide polymorphisms in TLR2 (Arg753Gln and -16934T>A) and TLR4 (Asp299Gly and Thr399Ile) were not associated with carotid artery intima-media thickness at baseline in genome-wide association studies of dia betes mellitus over a 3-year follow-up period 42 , and the TLR2 poly morphisms Arg677Trp or Arg753Gln, TLR4 polymorphisms Asp299Gly or Thr399Ile, and the TLR9 polymorphism -1237T>C were not suitable markers to predict susceptibility to T2DM or coronary artery disease in the Chinese population 43 .
Involvement of NLRs
NF-κB increases the transcription of pro-IL-1β through signalling pathways that are downstream of the activation of TLRs. pro-IL-1β is subsequently processed and cleaved to IL-1β by the NLRP3 inflammasome, which TLR2  TLR1  TLR2  TLR6  TLR10  TLR5  TLR2  TLR4   TLR7   TLR3   TLR8   TLR9   TRAF6 . TLR signalling consists of two distinct pathways; the TIRAP-MyD88-dependent and TRAM-TRIF-dependent cascades. TIRAP conducts the signal from TLR4 to MyD88 and TRAM mediates the signal from TLR4 to TRIF. The engagement of TLR7, TLR8, and TLR9 in the endosome membrane leads to the formation of a myddosome complex that consists of MyD88, IRAK1, and IRAK4. MyD88 adaptor-like protein (MAL) binds to specific lipid microdomains to stabilize MyD88 interactions and trigger the formation of the myddosome complex. The activation of IRAK1 induces TRAF6 activation followed by activation of TAK1, MAPKs, AP1, and NF-κB. TRAM is required for the activation of TRIF, which interacts with TRAF3, TRAF6, and RIPK1. TLR3 in the endosome recruits the TIR adaptor, TRIF, and mediates the TRIF-dependent pathway. TLR4 can also activate the TRAM-TRIF pathway following its CD14-dependent endocytosis and is associated with endosomal-bound TRAM. consists of NLRP3, ASC, and caspase-1 44 (FIG. 2) . TLRs and IL-1β are upregulated in T1DM and IL-1β is known to induce apoptosis of pancreatic β cells 45 . Two multicentre randomized clinical trials were conducted to examine the effects of IL-1 antagonism on pancreatic β cells 46 . Canakinumab (an anti-IL-1β antibody) and anakinra (an IL-1 receptor antagonist) were safe but not as effective as immunomodulatory drugs; the effects of combination therapy with agents that target the adaptive and innate immune systems requires further study. The NLRP3 rs10754558 single nucleotide polymorphism lies in the 3ʹ-untranslated region of the gene 47 . This polymorph ism is significantly associated with T1DM in patients of Brazilian origin (P = 0.004) and exerted a protective effect on the natural history of the disease 47 .
Nlrp1b was identified as a strong candidate gene for T1DM susceptibility in both NOD mice and NOR mice, which are insulitis resistant and diabetes free despite genetic similarity to NOD mice at numerous chromosomal regions. Nlrp1b belongs to the NLR gene family, which contributes to the assembly of the inflammasome, recruitment of caspase-1, and release of IL-1β 48 . Investigations into the role of the inflammasome in the development of T1DM have so far been limited and more research is required to answer the question as to whether targeting inflammasomes will exert beneficial effects in T1DM.
T2DM, insulin resistance, and obesity Subclinical and chronic inflammation in obesity and the metabolic syndrome can induce insulin resistance and T2DM, and T2DM associated with obesity is now considered an inflammatory chronic disease 49 . The low-grade inflammatory state in adipose tissue, skeletal muscle, liver, gastrointestinal tract, and pancreas develops in response to an excess of nutrient flux, and the innate immune response mediated by TLRs and NLRs provides an important link to insulin resistance 50 . Adipose tissue is an important site of inflammation and is host to various inflammatory cells, such as neutrophils, basophils, M1 and M2 macrophages, T H 1, T H 2, and T REG cells, CD8 + T cells, and B cells, and is an important source of various chemokines, cytokines, and adipokines that modulate inflammatory responses in obesity and T2DM 51 .
Involvement of TLRs TLR2. Mice lacking Tlr2 are substantially protected from diet-induced adiposity, insulin resistance, hypercholesterol aemia, hepatic steatosis, and macrophage infiltration, and levels of inflammatory cytokines are reduced compared to wild-type mice 52, 53 . Furthermore, the absence of TLR2 was shown to attenuate local inflammatory cytokine expression and enhance insulin action in the liver 54 . Although TLR2 is implicated in the inflammatory response in high-fat diet (HFD)-induced obesity in rodents and in human gene expression studies 55 , saturated and polyunsaturated fatty acids did not elicit proinflammatory effects in human adipose tissue and primary adipocyte cultures 56 . Conversely, administration of a HFD to healthy men for 1 week reduced the expression of TLR2 57 . Such discrepancies between animal and human investigations complicate the understanding of the molecular mechanisms underlying T2DM and obesity, and further clinical trials are required to confirm the benefits of inhibiting TLR2 signalling in affected patients.
TLR adaptor molecules. Intracellular adaptor molecules, such as MyD88, and signal transducers, such as IRAK and TRAF family members, can also act as ligands to TLRs and can activate NF-κB and members of the interferon response family. In addition to the MyD88-dependent pathway, TLR4 recruits TRIF to activate downstream signalling cascades and IRF3 (FIG. 1) . Myd88 -/-mice fed a HFD exhibited increased circulating levels of insulin, leptin, and cholesterol, which are associated with insulin and leptin resistance and development of severe T2DM 58 . The Myd88 -/-mice also had smaller islets and abnormal glucose tolerance after treatment with low-dose STZ 59 . Although these reports suggest a protective role of MyD88 in glucose metabolism, both Trif -/-and Myd88 -/-mice are protected against lard-induced white adipose tissue inflammation and impaired insulin sensitivity 60 . Furthermore, mice with a specific deletion of Myd88 in the central nervous system were protected from HFD-induced weight gain and leptin resistance induced by acute intra cerebroventricular injection of palmitate 61 .
Myd88
-/-RIP-B7.1 mice that express B7.1 (CD80) co-stimulatory molecules in pancreatic β cells were protected from dia betes mellitus following polyinosinic:polycytidylic (poly I:C) treatment -a synthetic double-stranded RNA and agonist of TLR3 62 . In addition, inducible intestinal epithelial cell-specific deletion of Myd88 in mice protected against the development of obesity, diabetes mellitus, and inflammation, which could be recapitulated following transplantation of the gut microbiota to germ-free recipient animals 63 .
The conflicting results obtained from Myd88
-/-mice could be explained by the complex crosstalk between the microbiota and acute phase emergency granulopoiesis that can occur within minutes of infection 64 . Microbiota-driven myelopoiesis that occurs at concentrations of microbial antigens and PAMPs below the threshold required for activation of an adaptive immune response is important for the surveillance of infection 64 . The crosstalk between the innate and adaptive immune response, where MyD88 relays the signals of TLRinduced IL-1 production, has been shown to be dispensable for T H 1 responses in the absence of T REG cells 65 . The innate immune system mediated by MyD88, however, is essential in protecting against infections, and inhibition of MyD88 in the treatment of T2DM and obesity should be considered carefully.
Obesity-associated inflammation
Three apparently distinct mechanisms have been proposed as major triggers for sustained obesity-associated inflammation. These mechanisms include TLR4 activation, changes in the gut microbiota, and endoplasmic reticulum stress. Extensive crosstalk also occurs between these three mechanisms, which will be discussed in more detail below.
TLR4. Changes in the gut microbiota, reduced defense barriers in the intestine, and increased leakage of LPS and fatty acids can lead to the activation of TLR4 pathways and inflammation 66 . Lack of Tlr4 in mice fed a HFD resulted in protection against obesity 67 , insulin resistance 68 , and inflammation in adipose tissues 69, 70 , liver, skeletal muscle 71 , and vasculature 72 . Specific deletion of Tlr4 in haemato poietic cells ameliorated insulin resistance in hepatic and adipose tissue 73 and deletion of Tlr4 in hepato cytes improved glucose tolerance, enhanced insulin sensitivity, and ameliorated hepatic steatosis in mice 74 . The agonists for TLR2 and TLR4, such as LPS and saturated free fatty acids, are involved in manipulating the signalling events via NF-κB-p65 nuclear trans loca tion and proinflammatory cytokine production that occur in adipose, liver, muscle and pancreatic β cells in animal models of insulin resistance and obesity 55, 75 (FIG. 1) .
The inflammatory pathway mediated by IL-6 and TNF is mainly induced by the activation of TLR2 and TLR4, as seen in adipose tissue samples obtained from adolescents with the metabolic syndrome 76 . Transwell co-culture of U937 mononuclear cells showed that the activation of TLR4 by LPS or palmitate induced the production of IL-6 and activation of MMP-1, which may be involved in adipose tissue remodeling and obesity 77 . However, human SW872 preadipocyte cells actively secrete HMGB1, which boosts production of IL-6 via RAGE and does not involve TLR2 or TRL4 signalling 78 . Evidence thus far suggests that free fatty acids do not directly bind to TLR4, and thus an endogenous ligand for TLR4 remains to be identified 79 . Fetuin-A has been implicated as an endogenous ligand for TLR4 and knockdown experiments in mice with HFD-induced insulin resistance resulted in downregulation of TLR4-mediated inflammatory signalling in adipose tissue 79 . S100A8 and S100A9 are endogenous DAMPs that belong to the S100 calgranulin family. These DAMPs can induce insulin resistance and TLR4 and NLRP3 inflammasome-dependent IL-1β production in adipose tissue, macro phages, and neutrophils in both mice and humans 80 . TAK-242, a small-molecule inhibitor of TLR4 signalling, provides complete protection against LPS-induced and non-esterified fatty acid-induced inflammation in muscle cells and partial protection against insulin resistance 81 . The identification of endogenous ligands and their inhibitors is required to facilitate the development of therapeutic agents to ameliorate inflammation, insulin resistance, and obesity.
Gut microbiota. Evidence that the composition of the gut microbiota differs between healthy individuals and obese and/or patients with T2DM has spurred investi gations into the link between the pathophysiology of metabolic diseases and the gut microbiota. Tlr2 -/-mice bred and maintained under germ-free conditions are protected from diet-induced insulin resistance 82 . Under non-germfree conditions these mice are characterized by insulin resistance and obesity associated with changes in the gut microbiota, including a threefold increase in Firmicutes and a slight increase in Bacteroidetes. 82, 83 These data suggest that TLR2 has an important role in maintaining healthy microbiota and preventing obesity and insulin resistance. Similarly, Tlr4 -/-mice fed a HFD demonstrated reduced intestinal permeability, increased plasma endotoxin and proinflammatory cytokine levels, and increased epididymal fat weight 84 . Interestingly, chronic intake of a HFD leads to severe pulmonary damage and mortality in Tlr2 -/-Tlr4 -/-mice 85 , which suggests that diet and innate immune deficiency have a strong impact on the composition of the gut microbiota and can lead to life-threatening conditions. In addition, bacterial flagellin-recognizing Tlr5 -/-mice exhibited hyper phasia and metabolic syndrome, which was transmissible to wild-type mice by gut microbiota transplantation 86 . Taken together, total loss of TLRs may induce harmful changes to the micro biota and can result in the development of insulin r esistance and obesity in experimental mouse models.
A study of patients with high expression levels of TLR5-signalling pathway genes in adipose tissues found that these individuals tended to have obese phenotypes, a higher abundance of flagellated Clostridium cluster XIV and a higher Firmicutes:Bacteroides ratio than indivi duals with low TLR5 expression levels 87 . These data suggest that upregulation of TLRs enhances the inflammatory response and induces insulin resistance and obesity. The interaction between the microbiota and TLRs can result in whole-body inflammation and insulin resistance; however, total knockout of TLRs such as Trl2 and Tlr4 also impairs the innate immune system and results in persistent inflammation in mice 88 . Thus, therapeutic interventions against TLRs in obesity and T2DM require specific attention to the changes in the gut microbiota induced by a HFD, as the complete blockade of TLRs has harmful effects in patients who are obese.
Endoplasmic reticulum stress. Substantial crosstalk also occurs between TLRs and endoplasmic reticulum stress. Tlr4 -/-mice fed a HFD were protected from endoplasmic reticulum stress compared to wild-type mice, as assessed by monitoring markers of endoplasmic reticulum stress such as BiP, C/EBP homologous protein (CHOP), spliced and un-spliced XBP1, and phospho-eIF2α 89 . Activation of the TLR4 pathway attenuates adaptive thermogenesis via endoplasmic reticulum stress in mice and might explain the development of compromised adaptive thermogenesis in patients who are obese 90 . Mice fed a HFD or administered a chronic low dose of LPS to activate TLR4 before cold acclimation, had reduced core body temperature and heat release, and elevated endoplasmic reticulum stress and autophagy compared to mice that had received a low-fat diet or had not received LPS 90 . Endoplasmic reticulum stress is also known to activate the NLRP3 inflammasome and induce apoptosis in pancreatic β cells 91, 92 . This scenario has been demonstrated in macrophages 93 and adipocytes 94 , and endoplasmic reticulum stress is sufficient for the production of IL-1β via the activation of NF-κB and the NLRP3 inflammasome.
Involvement of NLRs
NOD2. The NOD2 signalosome and the NLRP3 inflamma some are both involved in the pathogenesis of obesity and insulin resistance. Expression levels of Nod2 in spleno cytes were higher in C57BL/6 mice fed a HFD compared to control mice 95 . Furthermore, NOD2 contributes to the induction of inflammation through the activation of NF-κB and an HFD also increases Nod2 expression in hepatocytes and adipocytes 95 . Compared to wild-type mice, Nod2 -/-mice show increased inflammation of adipose tissue and the liver and exacer bated insulin resistance under an HFD, associated with bacterial translocation from the gut to adipose tissue and the liver 96 . NLRP3 inflammasome. The NLRP3 inflammasome has a major role in regulating the innate immune system through its interaction with thioredoxin-interacting protein (TXNIP). Txnip and Nlrp3 deficiency in mice result in similar phenotypes, with impaired activation of the NLRP3 inflammasome and improved glucose tolerance and insulin sensitivity 97 . The NLRP3 inflamma some senses lipotoxicity-induced increases in intracellular ceramide and induces caspase-1 cleavage in adipose tissue macrophages; Nlrp3 -/-mice are protected from insulin resistance and inflammasome activation in liver and adipose tissues 98 . Saturated fatty acids, such as palmitate, but not unsaturated oleate, induces activation of the NLRP3-ASC inflammasome inducing the production of caspase-1, IL-1β, and IL-18,and reducing glucose tolerance and insulin sensitivity 99 . In pancreatic islet cells, islet amyloid polypeptide also triggers the NLRP3 inflammasome and generation of mature IL-1β, which is reversed by treatment with glyburide 100 . Loss of Pycard substantially improved insulin action and secretion by ameliorating the production of pancreatic IL-1β and β-cell death caused by a long-term HFD in mice 101 . The NLRP3 inflammasome, TLR2, and TLR4 are triggers for islet inflammation in T2DM and the activation of macrophages in various tissues is also mediated by activation of the NLRP3 inflammasome 102 . Pancreatic β-cell failure in the Zucker diabetic fatty rat is associated with activation of the NLRP3-ASC inflammasome in M1 macrophages and infiltration into pancreatic islets 103 . Furthermore, S100A8 and S100A9 induces adipose tissue macrophages to promote TLR4-MyD88 and NLRP3 inflammasome-dependent IL-1β production and stimulate IL-1 receptors on bone marrow myeloid pro genitors to contribute to the prominent monocytosis and neutrophilia observed in obesity 80 .
NLRP3 interactions with the gut microbiota.
Although NLRP3 is actively involved in the development of insulin resistance and impairment of insulin secretion, the NLRP3 inflammasome also responds to changes in the gut microbiota that result from alterations in diet 104 . NLRP6 and NLRP3 inflammasomes and their effector IL-18 unexpectedly ameliorated the metabolic syndrome and slowed the progression of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis by modulating the microbiota 105 . Changes in the configuration of the gut microbiota as a result of inflammasome deficiency can cause exacerbation of hepatic steatosis and inflammation by the influx of TLR4 and TLR9 agonists into the portal circulation 105 . The hierarchy and tissue distribution of NLRs, complicated interactions between TLRs and NLRs, and alterations in intestinal micro biota associ ated with multiple inflammasome deficiencies could account for the conflicting findings regarding inflammasome activity and diet-induced inflammation. The beneficial and adverse effects of targeting the NLRP3 inflammasome should be considered in relation to changes in the gut microbiota.
NLRP3-IL-1 pathway.
Injection of LPS into db/db mice, which are obese, diabetic and dyslipidaemic, induced production of IL-1β in macrophages and greater innate immune-associated illness than in heterozygous db/ + mice 106 . The effects of LPS could be blocked by administration of an IL-1 receptor antagonist 106 . The activation of NLRP3 has an important role in the production of IL-1 in T2DM and it might be an important target for disease treatment 107, 108 . Various factors induce the NLRP3-IL-1 pathway, including islet amyloid polypeptide deposition in the pancreas 100 ; cholesterol crystals in atherosclerotic lesions 109 ; Kilham rat virus in the spleen and lymph nodes of a LEW1.WR1 model of T1DM 110 ; endoplasmic reticulum stress-inducing chemicals and the free fatty acid palmitate in macrophages 94 ; free fatty acids in atherosclerotic lesions 109 and adipose tissues 111 ; extracellular deposition of ATP and P2X4 receptors in kidney 112 ; TLR2-TLR6 and TRL4 ligands in pancreatic islets and macrophages 113 ; and IL-22 in CD4 + T cells 114 . In turn, various agents, such as α1-antitrypsin 115 , losartan (an angiotensin-receptor blocker) 116 , procyanidin B2 117 , and a FOXO1 inhibitor 118 , can block and suppress the NLRP3-IL-1 amplification loop, as has been shown in macrophages.
Autophagy. Autophagy is one of the main catabolic pathways responsible for maintaining intracellular homeostasis via the formation of autophagosomes and by interacting with endosome-lysosome pathways. The reduced capacity of autophagy with ageing leads to inflammation through NLRP3 inflammasome activation. Disturbed interplay between autophagy and inflammasomes is also linked to the pathogenesis of T2DM, obesity, and atherosclerosis 119 . Systemic impairment of autophagy by inducing haploinsufficiency of the essential autophagy gene (Atg7 +/-) in obese (ob/ob) mice aggravated insulin resistance with increased intracellular lipid content and proinflammatory changes 120 . Furthermore, mice with a Lyz2-Cre-mediated knockout of Atg5 in macrophages fed a HFD and administered LPS demonstrated systemic and hepatic inflammation 121 . Defects in macrophage autophagy results in abnormal macrophage polarization, with increased numbers of proinflammatory M1 macrophage and decreased numbers of anti-inflammatory M2 macro phages, and enhanced hepatic inflammation and liver injury associated with obesity 121 .
Effect of adipokines on NLRP3 inflammasomes. Finally, various adipokines, such as adiponectin, leptin, FGF-21, RBP-4, BMP-4 and BMP-7, vaspin, apelin, and progranu lin produced by adipocytes have a marked effect on the regulation of the inflammatory response in obesity and T2DM 122 . Leptin is an adipocyte-secreted hormone that inhibits food intake and stimulates energy expenditure; however, most obese individuals have hyperleptin aemia and exhibit leptin resistance 123 . Hyperleptinaemia is associated with subclinical inflammation in obese subjects and leptin enhances the secretion of IL-18 from human monocytes via activation of caspase-1 inflamma somes 124 . FGF-19 and FGF-21 belong to a subfamily of FGFs that function as hormones and act on over lapping sets of cell surface receptors composed of classic FGF receptors and the β−Klotho complex, which has been associated with the regulation of glucose and lipid metabolism during periods of fluctuating energy availability 125 . Pharmacologic application of FGF-19 and FGF-21 cause weight loss and improve insulin sensitivity and lipid metabolism 125 . A 2015 study suggested a link between FGF-21 signalling and inflammation 126 ; FGF-21 might also alleviate T2DM-associated vascular complications by inhibiting NF-κB-NLRP3 inflammasome-mediated inflammation 127 .
Atherosclerosis and NLRs.
Cholesterol crystals have been shown to cause inflammation and ultimately athero sclerotic lesions through the activation of the NLRP3 inflammasome 128 . Investigation of aortic pouch biopsy samples from patients with T2DM and atherosclerosis and studies in a pig model of T2DM reported downregulated levels of SIRT1 and AMPK 129 . AMPK phosphorylates SREBP at Ser-327, inhibiting its activity, and repressing SREBP-dependent lipogenesis 129 . Once the lipogenic programme is initiated, NLRP3, ASC, and IL-1β are activated and upregulated 129 . A comparison of aortas from patients undergoing coronary artery bypass graft with arterial tissue from non-atherosclerotic live kidney donors found elevated NLRP3 expression in tissue from patients with hypertension, diabetes mellitus, and in smokers, and a strong correlation between NLRP3 expression and with coronary severity scores 130 .
Diabetic nephropathy
During acute kidney injury (AKI), tissue necrosis produces endogenous agonists to stimulate PRRs and trigger the innate immune system 131 ; however, a functional role for PRRs in chronic kidney disease has been questioned. The release of endogenous molecules stimulates canonical signalling pathways via TLRs and NLRs and converges on the activation of proinflammatory responses 131 .
Involvement of TLRs
TLR2 and TLR4 signalling has been implicated in the pathogenesis of various kidney diseases, including AKI and glomerulonephritis, and might also have a role in kidney transplantation and urinary tract infections 8 . Emerging evidence indicates a pivotal role for TLR2 and TLR4 in the perpetuation of inflammation in diabetic nephropathy 132 . High glucose conditions induce the overexpression of TLRs, such as TLR2 and TLR4 in endothelial cells of adipose tissue 72, 133 , the retina 134 , coronary arteries 40 , and kidney tissues 135 . Endothelial cells exposed to fluctuating glucose concentrations induce TLR4 and TLR2 expression and this process has been associated with increased levels of NF-κB, IL-8, MCP-1, ICAM-1, and VCAM-1  (FIG. 3) . Induction of diabetes by STZ administration did not increase expression of glomerular ICAM-1 in mice with Tlr2 or Tlr4 deficiency 136 . Anti-adhesion molecule therapies may prevent macro phage infiltration in pancreatic islets, adipose tissues, liver, retina, atherosclerotic lesions and kidney tissues and might therefore have beneficial effects in patients with diabetes mellitus and diabetic vascular complications. Although an anti-ICAM-1 antibody (enlimomab) has been tested in clinical trials in the context of stroke 137 and prevention of acute rejection in renal transplant recipients 138 , no beneficial effects were elicited and no reports in the context of diabetic vascular complications, such as diabetic nephropathy, exist. Targeting TLR2 and TLR4 signalling pathways, however, might attenuate vascular inflammation in patients with diabetes mellitus and diabetic nephropathy. TLR2 and TLR4 inhibitors are being characterized in preclinical models of inflammatory disease and are being tested in clinical trials in individuals with obesity and T2DM 139 , although no trials are underway in patients with diabetic nephropathy 132 . The involvement of TLR2 and TLR4 in diabetic nephropathy is discussed in more detail below.
TLR2. TLR2 and MyD88-mediated signalling were increased in macrophages obtained from STZ-mice, and were blunted following complete ablation of Tlr2 140 . The characteristic features of diabetic nephropathy, such as renal hypertrophy, albuminuria, and podocyte loss were ameliorated in these Tlr2 -/-STZ-induced diabetic mice 140 . Furthermore, peritoneal and kidney macrophages were predominantly the pro-inflammatory M1 phenotype in wild-type mice, and macrophage phenotypic changes, podocyte loss and urinary albumin excretion were attenuated in the Tlr2 -/-mice 140 . In STZ-induced and HFD-induced diabetic mice, TLR2 localized on glomerular endothelial cells. Repeated administration of Porphyromonas gingivalis LPS enhanced urinary albumin excretion and production of IL-6, TNF and LTA (TNF-β) in glomeruli 141 . In human proximal tubular cells, HMGB1-induced NF-κB activation was prevented by TLR2 silencing, and the researchers of this study emphasized the importance of TLR2 as a mediator of NF-κB activation in diabetic nephropathy 142 .
TLR4.
In cultured mouse mesangial cells, high glucose (25 mM) increased Tlr4 mRNA but not Tlr2 mRNA expression, compared to low glucose (5.5 mM). Downstream signalling molecules, such as MyD88, IRF3, and TRAM were also markedly increased 143 . In patients with T2DM, increased numbers of CD14 + CD16
+ monocytes, TLR4 expression, and serum levels of IL-6 and CRP were higher compared to healthy control individuals 144 . Moreover, these biomarkers were further increased in uraemic patients with diabetic nephro pathy, compared to levels in patients with T2DM and in healthy controls 144 . Blockade of TLR4 signalling by GIT27 (an immunomodulatory agent that targets macrophages by inhibiting TLR4 and TLR2 and TLR6-mediated signalling pathways) in db/db mice resulted in improved glycaemic control, decreased urinary albumin excretion, and improved glomerulosclerosis 145 . Another TLR4 antagonist, CRX-526, substantially reduced albuminuria and blood urea nitrogen without altering blood glucose and systolic blood pressure in eNOS-knockout mice 146 .
Compared with Tlr4
-/-mice treated with STZ, wild-type mice treated with STZ demonstrated increased markers of fibrosis, such as type IV collagen and LTA (TNF-β), as well as increased macrophage immunostaining, NF-κB activity, and expression of TLR4, MyD88, IRF3, TNF, IL-6, and MCP-1 in kidney tissues 147 . Furthermore, podocyte number and podocin expression were decreased in wild-type mice treated with STZ, and increased in Tlr4 -/-mice 147 . This effect may be mediated by the prevention of podocyte injury and apoptosis by TLR4 inhibition 148, 149 .
Human studies have confirmed findings that glomerular expression of TLR4 is associated with an upregulation of TNF, IL-6, CCR2, CCL5, and CCR5 mRNAs and subsequent loss of renal function 150 . Taken together, these findings suggest that TLR4 is a promising target for the treatment of diabetic nephropathy by suppressing the inflammation process in glomeruli (FIG. 3) . Elevated levels of TNF and IL-6 have been detected in the sera of patients with diabetic nephropathy, where they correlate positively with elevated levels of human β-defensin, which stimulates TLR4 in dendritic cells 151 . Although therapeutic interventions for TNF and IL-6 by use of receptor fusion proteins and monoclonal antibodies were once regarded as an efficacious treatment for insulin resistance and diabetic nephropathy 152, 153 , no clinical data are available in the literature that prove the efficacy of inhibition of TNF and IL-6.
Involvement of NLRs
NOD2.
Various studies support a role for NOD2 in the pathogenesis of diabetic nephropathy 154 . NOD2 was upregulated in HFD-induced and STZ-induced diabetic mice and in kidney biopsy samples from patients with T2DM 154 . Furthermore, NOD2 was upregulated in podocytes treated with high glucose, AGEs, TNF, or Figure 3 | Innate immunity and inflammatory pathways in diabetic nephropathy and obesity-related kidney diseases. In podocytes, thioredoxin (TRX)-interacting protein (TXNIP), a pro-oxidative stress and pro-inflammatory factor, activates the NLRP3 inflammasome by interacting with NALP3 in podocytes exposed to high glucose 173 . Under a high fat diet, mice lacking P2×7r exhibit reduced NLRP3, ASC, mature caspase-1, IL-1β, and IL-18 174 . In cultured podocytes, inhibition of NADPH oxidase abrogates NALP3 inflammasome activation and IL-1β production, and eventually protects podocytes from high glucose-induced injury 159 . Mitochondrial reactive oxygen species (ROS) activate NLRP3 inflammasomes under conditions of high glucose or in the presence of advanced glycation end products (AGEs) 158 . ASC is a component of NLRP3 inflammasome and small hairpin RNA-transfection of Pycard in mice on a high fat diet attenuates proteinuria, albuminuria, podocyte foot process effacement and loss of podocyte slit diaphragm molecules 175 . Human podocytes cultured with sera from normoalbuminuric patients with type 1 diabetes mellitus and high lipopolysaccharide activity show downregulation of PDK1, an activator of the Akt cell survival pathway, and induction of apoptosis 148 . Both Tlr2 and Tlr4 knockout mice were protected from development of diabetic nephropathy 140, 147, 149 . In glomerular endothelial cells, mitochondrial ROS induced by high glucose and AGEs provokes NLRP3 activation and production of caspase-1 and IL-1β -/-mice were protected from a hyperglycaemia-induced reduction in nephrin expression 154 . Thus, NOD2 links renal injury to inflammation and insulin resistance in the podocyte in diabetic nephropathy 154 . RNA-binding protein human antigen (HuR) is upregulated in patients with diabetic nephropathy, and correlates with degree of proteinuria 155 . In vitro experiments using rat glomerular mesangial cells have indicated that high glucose can induce a prominent increase in cytoplasmic HuR, which allows HuR to bind to the 3ʹ-untranslated region of NOD2 and enhance the expression of NOD2 and mRNA stability 155 . NOD1 and NOD2 were initially implicated in the pathogenesis of AKI by canonical signalling events, whereby tissue necrosis produces endogenous agonists that stimulate NODs and activate proinflammatory responses 131 . NOD2 also elicits non-canonical signalling events in diabetic nephro pathy and affects LTA (TNF-β) signalling in tubular cells, glucose handling, nephrin expression in podocytes, and macrophage phenotypes 131 .
NLRP3. In addition to NOD2, NLRP3 inflammasomemediated inflammation is recognized in the development of kidney injury, and urate and lipids are generally considered danger signals in NLRP3 inflammasome activation. In an STZ-induced rat model of diabetic nephropathy with hyperuricaemia and dyslipidaemia, overexpression of NLRP3 inflammasome components (ASC and caspase-1) was associated with elevated IL-1β and IL-18 (FIG. 3) 
156
. Treatment with quercetin (a flavonoid) and allopurinol (a xanthine oxidase inhibitor) suppressed renal NLRP3 inflammasome activation and ameliorated diabetesassociated nephrotoxicity via anti-hyperuricaemic and anti-dyslipidaemic mechanisms 156, 157 . Extracellular ATP is another endogenous signal that activates the NLRP3 inflammasome via stimulation of P2X receptors, which results in the production of IL-1β and IL-18 112 . Apyrase consumes extracellular ATP and can block ATP-P2X4 signalling caused by high glucose, whereas the P2 receptor antagonist suramin, P2X receptor antagonist TNP-ATP, P2X4 selective antagonist 5-BDBD, and P2×4 gene silencing attenuated NLRP3 expression and ameliorated renal NLRP3 inflammasome activation 112 . Mitochondria-derived reactive oxygen species (ROS) induced by high glucose conditions also stimulates the NLRP3 inflammasome, and abolishing NLRP3 or caspase-1 expression in bone marrow-derived cells fails to protect mice against diabetic nephropathy. Mice with specific non-myeloid derived cell Nlrp3 deficiency, however, were protected against diabetic nephropathy despite transplantation of wild-type bone marrow 158 . In diabetic nephropathy, hyperuricaemia is a strong inducer of NLRP3 and IL-1 production, which contributes to the progression of disease 158 , and uric acidlowering agents might have therapeutic potential in diabetic nephropathy 156, 157 . Hyperglycaemia induces the expression of TXNIP, an inhibitor of thioredoxin, which causes subsequent activation of gp91 (phox), a subunit of NADPH oxidase, and NLRP3 159 . The inhib ition of NADPH oxidase or TXNIP in STZ-induced diabetic C57BL/6 mice resulted in inhibition of the NLRP3 inflammasome and production of IL-1. Overall, NADPH and/or TXNIP might be suitable targets for the treatment of diabetic nephropathy 159 . Targeting the inflammasome might be a potential therapeutic approach for diabetic nephropathy; however, whether NLRP3 is the best molecular target or whether upstream molecules, such as NADPH oxidase, TXNIP, P2X7R, or NOD2 are more appropriate targets remains to be elucidated (FIG. 3) .
Influence of chemokines
The activation of TLRs and/or NOD1 stimulates the expression of chemokines, such as MCP-1 (CCL2) in adipose tissues in obesity [160] [161] [162] [163] and in kidney tissue in hyperglycaemia (FIG. 3) . In particular, the expression of TLR2 and TLR4 was enhanced in rats with STZinduced diabetes mellitus 164, 165 and global deletion of Tlr4 in mice resulted in decreased renal inflammation and fibrosis associated with a reduction in the expression of MCP-1 147 . MCP-1 is a chemokine that binds to the CCR2 receptor that is expressed in monocytes and macrophages 166 . Activation of MCP-1 is driven by hyperglycaemia and glomerular haemodynamic perturbations in diabetes mellitus, and is an important target in the progression of diabetic nephropathy 167 . Investigation of human macro phages suggest that MCP-1 favours a shift from proinflammatory M1 macrophages to antiinflammatory M2 macrophages 168, 169 , and in an experimental animal model, macrophage polarization was shown to shift from an M1 phenotype in the early phase of diabetes mellitus to an M2 phenotype in the later phases of the disease 170 . Thus, inhibition of MCP-1 signalling might be beneficial in the treatment of diabetic nephropathy 170 . A CCR2 antagonist, CCX140-B, and an MCP-1 inhibitor, NOX-E36, have been developed and are currently under investigation in clinical trials 170 . The inhibition of MCP-1 might exert renoprotective effects in combination with renin-angiotensin-aldosterone system (RAAS) inhibition. Combination therapy with a RAAS inhibitor and the CCR2 antagonist CCX140-B is renoprotective, as assessed by change in urinary albumin to creatinine ratio, in patients with T2DM and diabetic nephropathy 171 .
Conclusions
Sustained inflammation in pancreatic islets during T1DM is mediated by TLR2 and TLR4. Under conditions of excessive nutrition and obesity, TLR4 mediates inflammation in both pancreatic islets and in kidney tissues. In T2DM, TLRs sense hyperglycaemia and potential metabolic harm and translate this information by eliciting chronic inflammation. Thus, inhibition of TLR2 and TLR4 signalling may be beneficial by suppressing inflammation and protecting pancreatic β cells and kidney tissues from a decline in insulin secretion and renal function in diabetic nephropathy.
The interaction between the microbiota and TLRs can provoke whole-body inflammation and insulin resistance. Interestingly, total loss of TLRs can also impair the innate immune system and enhance inflammation.
An active immune system has the potential to prevent the development and recurrence of cancer by immunosurveillance, but the tumour microenvironment can cause profound immune suppression and exhaustion 172 . TLR agonists activate both the innate and adaptive immune system and exert antiviral and anti tumour activities. Inhibition of TLRs might accelerate the development of de novo tumourigenesis and recurrence of malignancies in patients with diabetes and diabetic nephropathy, and the utility of TLR inhibitors must, therefore, be considered with caution.
In the development of obesity and T2DM, elevation of IL-1β is tightly associated with the development of insulin resistance and kidney injury. Activation of the NLRP3 inflammasome in adipose tissues, liver, and pancreatic islets is responsible for the development of obesity and T2DM. In diabetic nephropathy, the activation of NLRP3 inflammasome and production of IL-1β is also responsible for the development of diabetic nephropathy. Thus, targeting the NLRP3 inflammasome may be a potential therapeutic approach for both diabetes mellitus and diabetic nephropathy.
